Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.

[1]  J. Borrell,et al.  Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease. , 2015, Mini reviews in medicinal chemistry.

[2]  E. Novellino,et al.  Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors , 2015 .

[3]  D. Hadjipavlou-Litina,et al.  Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease. , 2015, Future medicinal chemistry.

[4]  E. Novellino,et al.  Synthetic spirocyclic endoperoxides: new antimalarial scaffolds , 2015 .

[5]  T. Gharbi,et al.  Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. , 2015, Future medicinal chemistry.

[6]  Stefano Alcaro,et al.  N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. , 2014, Journal of medicinal chemistry.

[7]  E. Novellino,et al.  Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. , 2014, Journal of medicinal chemistry.

[8]  Katarina Nikolic,et al.  Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids , 2014, Drug design, development and therapy.

[9]  J. Finberg.  Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. , 2014, Pharmacology & therapeutics.

[10]  Simone Brogi,et al.  Rational design of the first difluorostatone-based PfSUB1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[11]  Simone Brogi,et al.  Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation , 2014, CNS neuroscience & therapeutics.

[12]  Li Wang,et al.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[13]  Z. Leonenko,et al.  Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation , 2014, Biomolecules.

[14]  E. Novellino,et al.  Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation. , 2013, ACS medicinal chemistry letters.

[15]  D. Mousseau,et al.  An update on amine oxidase inhibitors: Multifaceted drugs , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  Simone Brogi,et al.  Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds. , 2013, European journal of medicinal chemistry.

[17]  Simone Brogi,et al.  Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. , 2013, Journal of medicinal chemistry.

[18]  A. Bush.  The metal theory of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[19]  E. Novellino,et al.  Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents. , 2012, Journal of medicinal chemistry.

[20]  D. Hadjipavlou-Litina,et al.  Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties. , 2012, Journal of medicinal chemistry.

[21]  F. Leonetti,et al.  Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. , 2011, Current medicinal chemistry.

[22]  F. J. Luque,et al.  Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. , 2010, Chemico-biological interactions.

[23]  Xiongwei Zhu,et al.  Oxidative stress in Alzheimer disease: A possibility for prevention , 2010, Neuropharmacology.

[24]  V. Andrisano,et al.  Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. , 2009, Journal of medicinal chemistry.

[25]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[26]  M. Giovannini,et al.  Cholinesterase inhibitors and beyond. , 2009, Current Alzheimer research.

[27]  D. Hadjipavlou-Litina,et al.  Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[28]  N. Durany,et al.  Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.

[29]  Ettore Novellino,et al.  Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. , 2008, Bioorganic & medicinal chemistry letters.

[30]  C. Harris,et al.  The chemical biology of nitric oxide: implications in cellular signaling. , 2008, Free radical biology & medicine.

[31]  Ettore Novellino,et al.  Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. , 2008, Journal of medicinal chemistry.

[32]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[33]  Maurizio Recanatini,et al.  Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. , 2007, Journal of medicinal chemistry.

[34]  T. Wisniewski,et al.  Disease modifying approaches for Alzheimer's pathology. , 2007, Current pharmaceutical design.

[35]  Maurizio Recanatini,et al.  A small molecule targeting the multifactorial nature of Alzheimer's disease. , 2007, Angewandte Chemie.

[36]  István A. Kovács,et al.  How to design multi-target drugs , 2007, Expert opinion on drug discovery.

[37]  Claire Mount,et al.  Alzheimer disease: progress or profit? , 2006, Nature Medicine.

[38]  T. Storr,et al.  Design of targeting ligands in medicinal inorganic chemistry. , 2006, Chemical Society reviews.

[39]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[40]  Ettore Novellino,et al.  Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. , 2005, Journal of medicinal chemistry.

[41]  J. Standridge.  Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. , 2004, The American journal of geriatric pharmacotherapy.

[42]  A. Dávalos,et al.  Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. , 2004, Journal of agricultural and food chemistry.

[43]  Math P. Cuajungco,et al.  Zinc takes the center stage: its paradoxical role in Alzheimer’s disease , 2003, Brain Research Reviews.

[44]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[45]  A. Marquet,et al.  Total synthesis of amiclenomycin, an inhibitor of biotin biosynthesis. , 2002, Chemistry.

[46]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[47]  S. Lewington,et al.  Tacrine for Alzheimer's disease , 1999 .

[48]  M. Rissel,et al.  Toxic Effects of Tacrine on Primary Hepatocytes and Liver Epithelial Cells in Culture , 1998, Cell Biology and Toxicology.

[49]  N. Panchuk-Voloshina,et al.  A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. , 1997, Analytical biochemistry.

[50]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[51]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[52]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[53]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[54]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[55]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[56]  J. Cummings,et al.  Treatment of Alzheimer's disease: current and future therapeutic approaches. , 2004, Reviews in neurological diseases.

[57]  D. Selkoe.  Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. , 2001, Journal of Alzheimer's disease : JAD.

[58]  C. Y. Huang.  Determination of binding stoichiometry by the continuous variation method: the Job plot. , 1982, Methods in enzymology.